

Supported in part by an educational grant from



International Society of Gastrointestinal Oncology

2010 Gastrointestinal Oncology Conference

September 23–25, 2010

ABSTRACTS

Pancreatic Cancer

abstr 1007

Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors

Jonathan Strosberg, Asima Cheema, Jill Weber, Domenico Coppola, Larry Kvols
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Background: The risk of metastatic spread among patients with early-stage surgically resected pancreatic neuroendocrine tumors has not been well established.

Methods: Patients with surgically resected localized or locally advanced pancreatic neuroendocrine tumors treated at the H. Lee Moffitt Cancer Center between 1999 and 2010 were assigned a stage (I-III) based on the new AJCC classification. Recurrence-free survival was measured for each stage. A separate analysis was performed excluding patients who had been referred to Moffitt Cancer Center after metastatic recurrence.

Results: 123 patients with non-metastatic, surgically-resected pancreatic neuroendocrine tumors were identified. 5-year recurrence-free survival correlated with AJCC stage ($p=0.01$; table 1).

Conclusions: The novel AJCC 7th Edition TNM classification for pancreatic neuroendocrine tumors is highly prognostic for recurrence in patients with surgically resected non-metastatic tumors.

Table 1: 5-year RFS rates of patients with surgically resected, non-metastatic pancreatic NETs stratified by the AJCC staging system

TNM Stage	Number of patients	5-year RFS	Number of patients*	5-year RFS*
Stage I	77	78%	64	90%
Stage II	40	53%	27	73%
Stage III	6	33%	3	66%

*Excluding patients who presented to Moffitt Cancer Center after metastatic recurrence